

# Irene Brana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2906920/publications.pdf>

Version: 2024-02-01

52  
papers

6,029  
citations

159358

30  
h-index

189595

50  
g-index

54  
all docs

54  
docs citations

54  
times ranked

8954  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. <i>Nature Cancer</i> , 2022, 3, 251-261.	5.7	44
2	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. <i>Journal of Clinical Oncology</i> , 2022, 40, 2321-2332.	0.8	79
3	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	0.8	17
4	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	3.2	10
5	Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. <i>Investigational New Drugs</i> , 2021, 39, 1275-1283.	1.2	9
6	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	3.6	54
7	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021, 5, 33.	2.3	5
8	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1508-e1513.	1.9	16
9	Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	0.8	100
10	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 168-178.	1.3	1
11	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz093.	1.4	126
12	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
13	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. <i>Gynecologic Oncology</i> , 2020, 159, 150-156.	0.6	43
14	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 322-328.	0.6	51
15	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. <i>JCO Precision Oncology</i> , 2020, 4, 505-513.	1.5	10
16	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020, 26, 992-994.	15.2	56
17	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1730-1736.	2.9	63
18	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 1915-1928.	6.3	1,804

#	ARTICLE	IF	CITATIONS
19	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019, 10, 2416.	5.8	150
20	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019, 25, 751-758.	15.2	362
21	New clinical trial designs in the era of precision medicine. <i>Molecular Oncology</i> , 2019, 13, 549-557.	2.1	89
22	Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2019, 107, 142-152.	1.3	208
23	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1 Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	3.4	235
24	Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3015-3015.	0.8	0
25	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	13.9	997
26	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 775-785.	1.7	64
27	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017, 8, 84659-84670.	0.8	13
28	Molecular screening programmes for precision medicine: lessons learned from personalized medicine trials. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 419-430.	0.4	1
29	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (tx) as predictor of clinical benefit (ClinBen) in early trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2572-2572.	0.8	2
30	Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6030-6030.	0.8	1
31	Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. <i>Drugs in Context</i> , 2016, 5, 1-8.	1.0	2
32	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- $\beta$ 2 receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 357-370.	1.2	90
33	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2015, 33, 710-719.	1.2	24
34	First-in-Human Dose Study of the Novel Transforming Growth Factor- $\beta$ 2 Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	3.2	199
35	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. <i>Seminars in Oncology</i> , 2015, 42, 775-787.	0.8	6
36	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1888-1895.	3.2	99

#	ARTICLE	IF	CITATIONS
37	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 49-59.	3.2	49
38	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. <i>Targeted Oncology</i> , 2015, 10, 111-123.	1.7	158
39	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 233-245.	3.2	142
40	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , 2014, 32, 1269-1277.	1.2	45
41	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 670-681.	1.2	165
42	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	1.2	50
43	Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 4260-4267.	0.8	83
44	Cardiotoxicity. , 2013, , 483-530.		2
45	Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF- $\beta$ ) receptor I kinase inhibitor, LY2157299 monohydrate (LY).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2016-2016.	0.8	12
46	Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5518-5518.	0.8	3
47	Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. <i>BMC Medicine</i> , 2012, 10, 161.	2.3	81
48	The oral transforming growth factor-beta (TGF- $\beta$ ) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2042-2042.	0.8	5
49	Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3014-3014.	0.8	1
50	Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3059-3059.	0.8	0
51	Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs. <i>Oncologist</i> , 2011, 16, 1729-1740.	1.9	117
52	Angiosarcoma of the Ovary: Is It Always a Lethal Disease?. <i>Journal of Clinical Oncology</i> , 2010, 28, e675-e677.	0.8	13